Company Profile
SynCore Biotechnology provides development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer
SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer, as well as SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials.
Additionally, it provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. It also distributes cameras under the epiCam name such as hand-held color, hand-held monochrome, and veterinary fundus cameras that is used in recording the progress of ophthalmology diseases
Choroidal blood flow measurement. The company has partnerships with Aresus, MacuCLEAR Inc. Its portfolio also includes Y-YBAR, Epipole, Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes NHRI. Incorporated in 2008, the company is headquartered in Yilan City, Taiwan. SynCore Biotechnology Co.,Ltd operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.